MX2011009281A - Conjugados de anticuerpo farmaco (adc) que enlazan a proteinas 24p4c12. - Google Patents
Conjugados de anticuerpo farmaco (adc) que enlazan a proteinas 24p4c12.Info
- Publication number
- MX2011009281A MX2011009281A MX2011009281A MX2011009281A MX2011009281A MX 2011009281 A MX2011009281 A MX 2011009281A MX 2011009281 A MX2011009281 A MX 2011009281A MX 2011009281 A MX2011009281 A MX 2011009281A MX 2011009281 A MX2011009281 A MX 2011009281A
- Authority
- MX
- Mexico
- Prior art keywords
- adc
- bind
- drug conjugates
- antibody drug
- proteins
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6863—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from stomach or intestines cancer cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3046—Stomach, Intestines
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cell Biology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La invención se refiere a un método para operar un dispositivo (1) para limpiar el escape de un motor de combustión interna (2) operado por un exceso de aire, donde el dispositivo (1) comprende al menos un aparato calentador (3) que está al menos parcialmente en contacto con el escape, que puede ser activado por medio de energía eléctrica y está diseñado al menos parcialmente con un recubrimiento de oxidación (4), donde: a) el al menos un aparato calentador (3) es calentado vía una primera meta especificada de temperatura (19), b) entonces se monitorea al menos la temperatura del al menos un aparato calentador (3), o la del gas de escape, y c) se provoca un incremento de la proporción de hidrógeno de escape, si al menos la temperatura del aparato calentador (3) o la del gas de escape ha alcanzado una temperatura de umbral (21), o hay una fase de carga baja (24) en el motor de combustión interna (2).
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15814309P | 2009-03-06 | 2009-03-06 | |
PCT/US2010/026429 WO2010111018A1 (en) | 2009-03-06 | 2010-03-05 | Antibody drug conjugates (adc) that bind to 24p4c12 proteins |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2011009281A true MX2011009281A (es) | 2012-07-30 |
Family
ID=42781369
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2011009281A MX2011009281A (es) | 2009-03-06 | 2010-03-05 | Conjugados de anticuerpo farmaco (adc) que enlazan a proteinas 24p4c12. |
Country Status (15)
Country | Link |
---|---|
US (2) | US8309093B2 (es) |
EP (1) | EP2403524A4 (es) |
JP (1) | JP2012519711A (es) |
KR (1) | KR20120034591A (es) |
CN (1) | CN102448486A (es) |
AU (1) | AU2010229192A1 (es) |
BR (1) | BRPI1013645A2 (es) |
CA (1) | CA2754531A1 (es) |
IL (1) | IL214983A0 (es) |
MX (1) | MX2011009281A (es) |
RU (1) | RU2011140491A (es) |
SG (1) | SG174259A1 (es) |
TW (1) | TW201043249A (es) |
WO (1) | WO2010111018A1 (es) |
ZA (1) | ZA201107293B (es) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2754531A1 (en) * | 2009-03-06 | 2010-09-30 | Seattle Genetics, Inc. | Antibody drug conjugates (adc) that bind to 24p4c12 proteins |
EP2686020B1 (en) | 2011-03-17 | 2017-02-22 | The University of Birmingham | Re-directed immunotherapy |
KR102356286B1 (ko) * | 2011-05-27 | 2022-02-08 | 암브룩스, 인코포레이티드 | 비-천연 아미노산 연결된 돌라스타틴 유도체를 함유하는 조성물, 이를 수반하는 방법, 및 용도 |
SG11201501286PA (en) * | 2012-08-23 | 2015-05-28 | Agensys Inc | Antibody drug conjugates (adc) that bind to 158p1d7 proteins |
US9353150B2 (en) | 2012-12-04 | 2016-05-31 | Massachusetts Institute Of Technology | Substituted pyrazino[1′,2′:1 ,5]pyrrolo[2,3-b]-indole-1,4-diones for cancer treatment |
RU2015129800A (ru) | 2012-12-21 | 2017-01-30 | Биоэллаенс К. В. | Гидрофильные саморазрушающиеся линкеры и их конъюгаты |
EP2777714A1 (en) | 2013-03-15 | 2014-09-17 | NBE-Therapeutics LLC | Method of producing an immunoligand/payload conjugate by means of a sequence-specific transpeptidase enzyme |
FR3005051A1 (fr) * | 2013-04-25 | 2014-10-31 | Pf Medicament | Derives de la dolastatine 10 et d'auristatines |
US20170043034A1 (en) * | 2014-01-24 | 2017-02-16 | Genentech, Inc. | Methods of using anti-steap1 antibodies and immunoconjugates |
UY36041A (es) | 2014-03-21 | 2015-09-30 | Abbvie Inc | Anticuerpos y conjugados de anticuerpo y fármaco anti-egfr |
CN106470708B (zh) | 2014-04-25 | 2019-12-31 | 皮埃尔法布雷医药公司 | 抗体-药物-缀合物和其用于治疗癌症的用途 |
JP6258523B2 (ja) | 2014-04-25 | 2018-01-10 | ピエール、ファーブル、メディカマン | Igf−1r抗体−薬物複合体および癌の処置のためのその使用 |
KR20170020868A (ko) | 2014-06-20 | 2017-02-24 | 바이오얼라이언스 씨.브이. | 항-폴레이트 수용체 알파 (fra) 항체-약물 컨쥬게이트 및 그것의 사용 방법 |
AU2015277100A1 (en) * | 2014-06-20 | 2017-02-02 | Abgenomics International Inc. | HER2 antibody-drug conjugates |
EP3160513B1 (en) | 2014-06-30 | 2020-02-12 | Glykos Finland Oy | Saccharide derivative of a toxic payload and antibody conjugates thereof |
BR122020025870B1 (pt) | 2014-12-23 | 2024-01-09 | Nbe-Therapeutics Ag | Método para a produção de um conjugado de proteína de ligaçãofármaco |
US10472422B2 (en) | 2016-01-08 | 2019-11-12 | Abgenomics International Inc. | Tetravalent anti-PSGL-1 antibodies and uses thereof |
WO2017197045A1 (en) | 2016-05-11 | 2017-11-16 | Movassaghi Mohammad | Convergent and enantioselective total synthesis of communesin analogs |
CN109562169A (zh) | 2016-06-08 | 2019-04-02 | 艾伯维公司 | 抗cd98抗体及抗体药物偶联物 |
WO2017214339A1 (en) | 2016-06-08 | 2017-12-14 | Abbvie Inc. | Anti-b7-h3 antibodies and antibody drug conjugates |
WO2017214322A1 (en) | 2016-06-08 | 2017-12-14 | Abbvie Inc. | Anti-b7-h3 antibodies and antibody drug conjugates |
CN116284404A (zh) | 2016-06-08 | 2023-06-23 | 艾伯维公司 | 抗b7-h3抗体和抗体药物偶联物 |
AU2017277916A1 (en) | 2016-06-08 | 2019-01-03 | Abbvie Inc. | Anti-CD98 antibodies and antibody drug conjugates |
WO2018209239A1 (en) | 2017-05-11 | 2018-11-15 | Massachusetts Institute Of Technology | Potent agelastatin derivatives as modulators for cancer invasion and metastasis |
CA3074840A1 (en) | 2017-09-07 | 2019-03-14 | Dragonfly Therapeutics, Inc. | Proteins binding nkg2d, cd16 and nectin4 |
US10640508B2 (en) | 2017-10-13 | 2020-05-05 | Massachusetts Institute Of Technology | Diazene directed modular synthesis of compounds with quaternary carbon centers |
WO2020131697A2 (en) | 2018-12-17 | 2020-06-25 | Revitope Limited | Twin immune cell engager |
US11535634B2 (en) | 2019-06-05 | 2022-12-27 | Massachusetts Institute Of Technology | Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof |
AR124681A1 (es) | 2021-01-20 | 2023-04-26 | Abbvie Inc | Conjugados anticuerpo-fármaco anti-egfr |
Family Cites Families (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4742000A (en) | 1986-05-02 | 1988-05-03 | University Of Chicago | Antibody to human progesterone receptor and diagnostic materials and methods |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US6130237A (en) | 1996-09-12 | 2000-10-10 | Cancer Research Campaign Technology Limited | Condensed N-aclyindoles as antitumor agents |
US20030082546A1 (en) | 1996-11-06 | 2003-05-01 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
US6800746B2 (en) | 1997-02-25 | 2004-10-05 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of prostate cancer |
US6956108B2 (en) | 1997-06-16 | 2005-10-18 | Genentech, Inc. | PRO1184 antibodies |
US7109318B2 (en) | 1997-06-16 | 2006-09-19 | Genentech, Inc. | Nucleic acids encoding PRO830 |
US7393663B2 (en) | 1997-08-01 | 2008-07-01 | Serono Genetics Institute S.A. | Expressed sequence tags and encoded human proteins |
US7160985B2 (en) | 1997-10-29 | 2007-01-09 | Genentech, Inc. | Pro180 polypeptide |
WO1999040189A2 (en) | 1998-02-09 | 1999-08-12 | Genset | Cdnas encoding secreted proteins |
US6747137B1 (en) | 1998-02-13 | 2004-06-08 | Genome Therapeutics Corporation | Nucleic acid sequences relating to Candida albicans for diagnostics and therapeutics |
US6551795B1 (en) | 1998-02-18 | 2003-04-22 | Genome Therapeutics Corporation | Nucleic acid and amino acid sequences relating to pseudomonas aeruginosa for diagnostics and therapeutics |
US20030050465A1 (en) | 1998-08-10 | 2003-03-13 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
US7109003B2 (en) | 1998-12-23 | 2006-09-19 | Abgenix, Inc. | Methods for expressing and recovering human monoclonal antibodies to CTLA-4 |
EE05627B1 (et) | 1998-12-23 | 2013-02-15 | Pfizer Inc. | CTLA-4 vastased inimese monoklonaalsed antikehad |
US20030190669A1 (en) | 1998-12-30 | 2003-10-09 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
CA2296792A1 (en) | 1999-02-26 | 2000-08-26 | Genset S.A. | Expressed sequence tags and encoded human proteins |
EP2365081A3 (en) | 1999-04-12 | 2012-07-18 | Agensys, Inc. | 13 Transmembrane protein expressed in prostate cancer |
US6943235B1 (en) | 1999-04-12 | 2005-09-13 | Agensys, Inc. | Transmembrane protein expressed in prostate cancer |
US7244827B2 (en) | 2000-04-12 | 2007-07-17 | Agensys, Inc. | Nucleic acid and corresponding protein entitled 24P4C12 useful in treatment and detection of cancer |
EP1074617A3 (en) | 1999-07-29 | 2004-04-21 | Research Association for Biotechnology | Primers for synthesising full-length cDNA and their use |
FR2800750B1 (fr) | 1999-11-05 | 2003-01-31 | Centre Nat Rech Scient | Proteines membranaires ctl (choline transporter like) impliquees dans le transport de la choline |
US20020192763A1 (en) | 2000-04-17 | 2002-12-19 | Jiangchun Xu | Compositions and methods for the therapy and diagnosis of prostate cancer |
US7442765B2 (en) | 2000-08-24 | 2008-10-28 | Genentech, Inc. | Secreted transmembrane polypeptides and nucleic acids encoding the same |
US20030099974A1 (en) | 2001-07-18 | 2003-05-29 | Millennium Pharmaceuticals, Inc. | Novel genes, compositions, kits and methods for identification, assessment, prevention, and therapy of breast cancer |
US20030073623A1 (en) | 2001-07-30 | 2003-04-17 | Drmanac Radoje T. | Novel nucleic acid sequences obtained from various cDNA libraries |
AR039067A1 (es) | 2001-11-09 | 2005-02-09 | Pfizer Prod Inc | Anticuerpos para cd40 |
WO2003070902A2 (en) | 2002-02-20 | 2003-08-28 | Incyte Corporation | Receptors and membrane-associated proteins |
ES2556641T3 (es) | 2002-07-31 | 2016-01-19 | Seattle Genetics, Inc. | Conjugados de fármacos y su uso para tratar cáncer, una enfermedad autoinmune o una enfermedad infecciosa |
AU2002352976B2 (en) * | 2002-11-27 | 2007-11-08 | Agensys, Inc. | Nucleic acid corresponding protein entitled 24P4C12 useful in treatment and detection of cancer |
SG195524A1 (en) | 2003-11-06 | 2013-12-30 | Seattle Genetics Inc | Monomethylvaline compounds capable of conjugation to ligands |
WO2006017538A2 (en) * | 2004-08-03 | 2006-02-16 | Dyax Corp. | Hk1-binding proteins |
DK1912677T3 (da) * | 2005-06-20 | 2014-01-13 | Psma Dev Company L L C | PSMA-antistof-lægemiddel-konjugater |
WO2007114979A2 (en) | 2006-02-17 | 2007-10-11 | Genentech, Inc. | Gene disruptons, compositions and methods relating thereto |
US8039597B2 (en) | 2007-09-07 | 2011-10-18 | Agensys, Inc. | Antibodies and related molecules that bind to 24P4C12 proteins |
WO2009033094A2 (en) * | 2007-09-07 | 2009-03-12 | Agensys, Inc. | Antibodies and related molecules that bind to 24p4c12 proteins |
CA2754531A1 (en) * | 2009-03-06 | 2010-09-30 | Seattle Genetics, Inc. | Antibody drug conjugates (adc) that bind to 24p4c12 proteins |
-
2010
- 2010-03-05 CA CA2754531A patent/CA2754531A1/en not_active Abandoned
- 2010-03-05 KR KR1020117023550A patent/KR20120034591A/ko not_active Application Discontinuation
- 2010-03-05 WO PCT/US2010/026429 patent/WO2010111018A1/en active Application Filing
- 2010-03-05 RU RU2011140491/10A patent/RU2011140491A/ru not_active Application Discontinuation
- 2010-03-05 JP JP2011553153A patent/JP2012519711A/ja active Pending
- 2010-03-05 BR BRPI1013645A patent/BRPI1013645A2/pt not_active IP Right Cessation
- 2010-03-05 CN CN2010800203364A patent/CN102448486A/zh active Pending
- 2010-03-05 EP EP10756560A patent/EP2403524A4/en not_active Withdrawn
- 2010-03-05 MX MX2011009281A patent/MX2011009281A/es unknown
- 2010-03-05 SG SG2011063930A patent/SG174259A1/en unknown
- 2010-03-05 AU AU2010229192A patent/AU2010229192A1/en not_active Abandoned
- 2010-03-05 US US12/718,902 patent/US8309093B2/en active Active
- 2010-03-08 TW TW099106660A patent/TW201043249A/zh unknown
-
2011
- 2011-09-05 IL IL214983A patent/IL214983A0/en unknown
- 2011-10-05 ZA ZA2011/07293A patent/ZA201107293B/en unknown
-
2012
- 2012-11-08 US US13/672,419 patent/US20130136756A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US8309093B2 (en) | 2012-11-13 |
CN102448486A (zh) | 2012-05-09 |
WO2010111018A8 (en) | 2011-03-03 |
IL214983A0 (en) | 2011-11-30 |
TW201043249A (en) | 2010-12-16 |
ZA201107293B (en) | 2012-06-27 |
EP2403524A1 (en) | 2012-01-11 |
BRPI1013645A2 (pt) | 2019-07-02 |
SG174259A1 (en) | 2011-10-28 |
CA2754531A1 (en) | 2010-09-30 |
JP2012519711A (ja) | 2012-08-30 |
RU2011140491A (ru) | 2013-04-20 |
US20100330107A1 (en) | 2010-12-30 |
KR20120034591A (ko) | 2012-04-12 |
WO2010111018A1 (en) | 2010-09-30 |
EP2403524A4 (en) | 2012-09-26 |
US20130136756A1 (en) | 2013-05-30 |
AU2010229192A1 (en) | 2011-09-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12017501461A1 (en) | Antibody drug conjugates (adc) that bind to 191p4d12 proteins | |
MX2011009281A (es) | Conjugados de anticuerpo farmaco (adc) que enlazan a proteinas 24p4c12. | |
EP2533804A4 (en) | CONJUGATES ANTIBODIES-MEDICINES (ADC) THAT BIND PROTEINS 161P2F10B | |
PH12015500392A1 (en) | Antibody drug conjugates (adc) that bind to 158p1d7 proteins | |
PH12017501580B1 (en) | Antibody drug conjugates (adc) that bind to flt3 proteins | |
PH12016500214A1 (en) | Antibody drug conjugates (adc) that bind to cd37 proteins | |
NZ598524A (en) | Therapeutic dll4 binding proteins | |
UA94734C2 (ru) | ТЕРАПЕВТИЧЕСКОЕ АНТИТЕЛО, КОТОРОЕ СВЯЗЫВАЕТСЯ С b-АМИЛОИДНЫМ ПЕПТИДОМ | |
UA104585C2 (ru) | Композиция, содержащая антитело, которое связывается с доменом ii her2, и его кислые варианты | |
BRPI0317376B8 (pt) | proteína de fusão de anticorpo-il2 designada como hu14.18-il2, usos da mesma, vetor e composição farmacêutica | |
MX2009006327A (es) | Compuestos heterociclicos y metodos de uso de los mismos. | |
EP2759302A3 (en) | 4F-benzoyl-TN14003 combined with rituximab for use in the treatment of a tumour | |
EP2175879A4 (en) | TREATMENT OF DISEASES ASSOCIATED WITH PRION PROTEIN | |
UA99601C2 (ru) | Применение антитела к cd151 для лечения первичных опухолей | |
GB0507598D0 (en) | Composition | |
AU2017236047B2 (en) | Antibody drug conjugates (ADC) that bind to 191P4D12 proteins | |
TH160954A (th) | แอนติบอดีดรักคอนจูเกต (adc) ที่จับกับโปรตีน 191p4d12 |